PMID: 7539270Jan 1, 1995Paper

FK 506 versus cyclosporin in the prevention of renal allograft rejection--European pilot study: six-week results

Transplant International : Official Journal of the European Society for Organ Transplantation
S SchleibnerD Mayer

Abstract

FK 506 was compared with cyclosporin in a randomised trial in good-risk cadaveric renal transplant recipients. The objective was to evaluate whether oral FK 506 dosing was viable and whether blood concentrations in the range 10-20 ng/ml would prove to be practical. Thirty-one adult patients were randomised to FK 506 and 16 to cyclosporin. Both groups received an identical regimen of azathioprine and corticosteroids. Serum creatinine concentrations decreased rapidly in both groups with mean values below 200 mumol/l within 2 weeks. One graft in the cyclosporin group was lost due to renal vein thrombosis. During the 6-week study period, 19.4% of patients on FK 506 and 31.3% on cyclosporin experienced acute rejection. One patient in each group experienced corticosteroid-resistant rejection that responded to anti-lymphocyte therapy. Infections were reported in 51.6% of the FK 506 group compared with 37.5% of the cyclosporin group. The spectrum of adverse events was similar in both groups. However, minor neurological disorders were more common in the FK 506 group (54.8% versus 6.3%) whereas hypertension was less common (48.8% versus 75.0%). The results indicate that oral FK 506 rapidly achieves therapeutic blood concentrations and is...Continue Reading

References


❮ Previous
Next ❯

Citations

Feb 1, 1997·Transplantation Proceedings·R Shapiro
Dec 5, 1998·Transplantation Proceedings·B L GohS Y Tan
Jul 10, 2001·International Journal of Urology : Official Journal of the Japanese Urological Association·S SatohT Kato
Dec 27, 1996·Transplantation·R ShapiroT E Starzl
Jul 27, 2001·Transplantation·J P SquiffletUNKNOWN European Tacrolimus-MMF Renal Study Group
Sep 1, 2016·Health Technology Assessment : HTA·Tracey Jones-HughesRob Anderson
Oct 20, 2005·The Cochrane Database of Systematic Reviews·A WebsterJ C Craig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Transplant International : Official Journal of the European Society for Organ Transplantation
G Thiel
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
P Sweny
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
G M Danovitch
© 2021 Meta ULC. All rights reserved